Lifeline BioTechnologies, Inc.

Lifeline BioTechnologies, Inc.

OOTC:LLBO
0.00
USD
+0.00
(+33.33%)
Lifeline BioTechnologies, Inc.
OTC:LLBO
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available
Business
Lifeline Biotechnologies, Inc. (LLBO) develops and commercializes innovative medical diagnostic technologies focused on point-of-care testing for infectious diseases and critical health conditions. The company offers the ABT-7500 automated workstation, which performs nucleic acid extraction, purification, and real-time PCR amplification for detecting pathogens such as SARS-CoV-2, influenza, and other respiratory viruses; the ABT-4500 semi-automated nucleic acid extraction system for high-throughput sample preparation; and related molecular diagnostic assays and reagents for clinical laboratories and healthcare providers. These products enable rapid, accurate diagnostics with minimal hands-on time, targeting hospitals, clinics, and point-of-care settings primarily in the United States. Founded in 2010 and headquartered in Virginia Beach, Virginia, Lifeline Biotechnologies operates within the biotechnology and diagnostics industry, serving the healthcare sector with a focus on molecular diagnostics. In recent developments, the company expanded its product portfolio with enhancements to its PCR-based testing platforms to address emerging infectious disease threats as of 2025, while maintaining strategic partnerships with clinical reference labs for assay validation and distribution.